FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2159368077> ?p ?o ?g. }

• W2159368077 abstract "Despite the proven success of hormonal therapy for prostate cancer using chemical or surgical castration, most patients eventually will progress to a phase of the disease that is metastatic and shows resistance to further hormonal manipulation. This has been termed metastatic castrate-resistant prostate cancer (mCRPC). Despite this designation, however, there is evidence that androgen receptor (AR)-mediated signaling and gene expression can persist in mCRPC, even in the face of castrate levels of androgen. This may be due in part to the upregulation of enzymes involved in androgen synthesis, the overexpression of AR, or the emergence of mutant ARs with promiscuous recognition of various steroidal ligands. The therapeutic options were limited and palliative in nature until trials in 2004 demonstrated that docetaxel chemotherapy could significantly improve survival. These results established first-line docetaxel as the standard of care for mCRPC. After resistance to further docetaxel therapy develops, treatment options were once again limited. Recently reported results from phase 3 trials have shown that additional therapy with the novel taxane cabazitaxel (with prednisone), or treatment with the antiandrogen abiraterone (with prednisone) could improve survival for patients with mCRPC following docetaxel therapy. Compared with mitoxantrone/prednisone, cabazitaxel/prednisone significantly improved overall survival, with a 30% reduction in rate of death, in patients with progression of mCRPC after docetaxel therapy in the TROPIC trial. Similarly, abiraterone acetate (an inhibitor of androgen biosynthesis) plus prednisone significantly decreased the rate of death by 35% compared with placebo plus prednisone in mCRPC patients progressing after prior docetaxel therapy in the COU-AA-301 trial. Results of these trials have thus established two additional treatment options for mCRPC patients in the post-docetaxel space. In view of the continued AR-mediated signaling on mCRPC, results from additional phase 3 studies with novel antiandrogens which are directed at inhibition of the AR (e.g., MDV3100), as well as other agents, are awaited with interest and may further expand the treatment choices for this difficult-to-manage population of patients." @default.
• W2159368077 created "2016-06-24" @default.
• W2159368077 creator A5002020225 @default.
• W2159368077 date "2011-04-23" @default.
• W2159368077 modified "2023-10-17" @default.
• W2159368077 title "Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space" @default.
• W2159368077 cites W1488048258 @default.
• W2159368077 cites W1854708637 @default.
• W2159368077 cites W1893347245 @default.
• W2159368077 cites W1975609403 @default.
• W2159368077 cites W2038396278 @default.
• W2159368077 cites W2055944905 @default.
• W2159368077 cites W2057734107 @default.
• W2159368077 cites W2076339819 @default.
• W2159368077 cites W2077301757 @default.
• W2159368077 cites W2077342518 @default.
• W2159368077 cites W2080439368 @default.
• W2159368077 cites W2083926838 @default.
• W2159368077 cites W2085540431 @default.
• W2159368077 cites W2092172518 @default.
• W2159368077 cites W2097226696 @default.
• W2159368077 cites W2101954532 @default.
• W2159368077 cites W2103959341 @default.
• W2159368077 cites W2106498871 @default.
• W2159368077 cites W2111199038 @default.
• W2159368077 cites W2113569308 @default.
• W2159368077 cites W2119504728 @default.
• W2159368077 cites W2120292596 @default.
• W2159368077 cites W2123526148 @default.
• W2159368077 cites W2126504358 @default.
• W2159368077 cites W2130803372 @default.
• W2159368077 cites W2134256060 @default.
• W2159368077 cites W2140855177 @default.
• W2159368077 cites W2141255350 @default.
• W2159368077 cites W2141569270 @default.
• W2159368077 cites W2151930316 @default.
• W2159368077 cites W2155846302 @default.
• W2159368077 cites W2158732421 @default.
• W2159368077 cites W2158734599 @default.
• W2159368077 cites W2162390569 @default.
• W2159368077 cites W2164660587 @default.
• W2159368077 cites W2165542862 @default.
• W2159368077 cites W2165782799 @default.
• W2159368077 cites W2170544517 @default.
• W2159368077 cites W4234937677 @default.
• W2159368077 cites W4241416564 @default.
• W2159368077 cites W597275420 @default.
• W2159368077 cites W99134297 @default.
• W2159368077 doi "https://doi.org/10.1186/1756-8722-4-18" @default.
• W2159368077 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3102641" @default.
• W2159368077 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21513551" @default.
• W2159368077 hasPublicationYear "2011" @default.
• W2159368077 type Work @default.
• W2159368077 sameAs 2159368077 @default.
• W2159368077 citedByCount "55" @default.
• W2159368077 countsByYear W21593680772012 @default.
• W2159368077 countsByYear W21593680772013 @default.
• W2159368077 countsByYear W21593680772014 @default.
• W2159368077 countsByYear W21593680772015 @default.
• W2159368077 countsByYear W21593680772016 @default.
• W2159368077 countsByYear W21593680772017 @default.
• W2159368077 countsByYear W21593680772018 @default.
• W2159368077 countsByYear W21593680772019 @default.
• W2159368077 countsByYear W21593680772020 @default.
• W2159368077 countsByYear W21593680772021 @default.
• W2159368077 countsByYear W21593680772022 @default.
• W2159368077 countsByYear W21593680772023 @default.
• W2159368077 crossrefType "journal-article" @default.
• W2159368077 hasAuthorship W2159368077A5002020225 @default.
• W2159368077 hasBestOaLocation W21593680771 @default.
• W2159368077 hasConcept C121608353 @default.
• W2159368077 hasConcept C126322002 @default.
• W2159368077 hasConcept C143998085 @default.
• W2159368077 hasConcept C2775832370 @default.
• W2159368077 hasConcept C2776551883 @default.
• W2159368077 hasConcept C2776694085 @default.
• W2159368077 hasConcept C2777511904 @default.
• W2159368077 hasConcept C2777899217 @default.
• W2159368077 hasConcept C2778720950 @default.
• W2159368077 hasConcept C2778971682 @default.
• W2159368077 hasConcept C2780192828 @default.
• W2159368077 hasConcept C2780923524 @default.
• W2159368077 hasConcept C2781190966 @default.
• W2159368077 hasConcept C530470458 @default.
• W2159368077 hasConcept C61367390 @default.
• W2159368077 hasConcept C71924100 @default.
• W2159368077 hasConceptScore W2159368077C121608353 @default.
• W2159368077 hasConceptScore W2159368077C126322002 @default.
• W2159368077 hasConceptScore W2159368077C143998085 @default.
• W2159368077 hasConceptScore W2159368077C2775832370 @default.
• W2159368077 hasConceptScore W2159368077C2776551883 @default.
• W2159368077 hasConceptScore W2159368077C2776694085 @default.
• W2159368077 hasConceptScore W2159368077C2777511904 @default.
• W2159368077 hasConceptScore W2159368077C2777899217 @default.
• W2159368077 hasConceptScore W2159368077C2778720950 @default.
• W2159368077 hasConceptScore W2159368077C2778971682 @default.
• W2159368077 hasConceptScore W2159368077C2780192828 @default.
• W2159368077 hasConceptScore W2159368077C2780923524 @default.
• W2159368077 hasConceptScore W2159368077C2781190966 @default.
• W2159368077 hasConceptScore W2159368077C530470458 @default.

• next